To date, DEINOVE is the only French biotech with a small molecule in Phase II clinical development, fully owned by the company, in the field of antibiotics.
DEINOVE builds a portfolio of first-in-class antimicrobial candidates, which places it among the major players in the field, by bringing together a European network of expertise.